Supplementary Material for: Acute Arteriovenous Access Failure: Long-Term Outcomes of Endovascular Salvage and Assessment of Co-Variates Affecting Patency

  • Milind D Nikam (Creator)
  • James Ritchie (Creator)
  • Anuradha Jayanti (Creator)
  • Ondina A Bernstein (Creator)
  • Leonard Ebah (Creator)
  • Paul Brenchley (Creator)
  • Alastair Hutchison (Creator)
  • Nicholas Chalmers (Creator)
  • Sandip Mitra (Creator)



<b><i>Aims:</i></b> This study reports long-term outcomes after endovascular salvage (EVS) for acute dialysis fistula/graft dysfunction. <b><i>Methods:</i></b> All patients presenting with acute fistula or graft dysfunction, excluding primary failures, referred for endovascular salvage were included in this single-centre prospective study. <b><i>Results:</i></b> Altogether, 410 procedures were carried out in 232 patients. Overall, the incidence of thrombosis/occlusion (per patient-year) was 0.12 for fistulae and 0.9 for grafts. The anatomical success rate for EVS was 94% for fistulae and 92% for grafts. Primary patency rates for fistulae at 1, 6, 12, 24 and 36 months were 82, 64, 44, 34 and 26%, respectively, whereas secondary patency rates were 88, 84, 74, 69 and 61%, respectively. Primary patency rates for grafts at 1, 6 and 12 months were 50, 14 and 8%. The overall rate of complications was 6% with no incidence of symptomatic pulmonary embolism. In a Cox regression model, upper-arm location of fistula (HR 1.9, p = 0.04, n = 144) was associated with lower primary patency, whereas the presence of thrombosis was associated lower primary (HR 1.9, p = 0.004, n = 144) and secondary patency (HR 3.7, p &lt; 0.001, n = 144). Aspirin therapy was associated with longer primary patency (HR 0.6, p = 0.02, n = 144) and secondary patency (HR 0.58, p = 0.08, n = 144). <b><i>Conclusion:</i></b> EVS is effective but longer-term outcomes are poor. Presence of thrombosis portends poor fistula survival and strategies for prevention need attention. Balloon maceration, our preferred declotting technique, is safe and the most cost-effective method. Aspirin therapy for patients presenting with failure of fistulae deserves further investigation.
Date made available6 Mar 2015


  • Arteriovenous access
  • Arteriovenous fistula
  • Arteriovenous shunt
  • Haemodialysis
  • Vascular access thrombosis

Cite this